Characteristics of Obstructive Sleep Apnea Patients With Hypertension and Factors Associated With Autotitration Acceptance

Xuan Zhang¹,², Ning Zhang²,³,⁴, Yang Yang²,³, Shuo Wang²,³, Ping Yu¹,², Bo-Yuan Guan²,³ and Chun-Xue Wang²,³,⁴,⁵*

¹ Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China, ² Department of Neuropsychiatry and Behavioral Neurology and Clinical Psychology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China, ³ China National Clinical Research Center for Neurological Diseases, Beijing, China, ⁴ Department of Clinical Psychology, Capital Medical University, Beijing, China, ⁵ Beijing Institute of Brain Disorders, Beijing, China

In order to explore the characteristics and treatment status of obstructive sleep apnea (OSA) patients with hypertension, a retrospective study was conducted on 306 patients admitted from October 2018 to December 2019. According to the apnea hypopnea index (AHI), OSA patients with hypertension were divided into three groups: 69 cases were mild OSA (5 ≤ AHI < 15), 86 cases were moderate (15 ≤ AHI < 30), and 151 cases were severe (AHI ≥ 30). Compared with patients in the mild and moderate groups, the severe group had more male patients, with higher body mass index (BMI) and non-rapid eye movement stage 1 accounted for total sleep time (N1%), and lower non-rapid eye movement stage 2 accounted for total sleep time (N2%), average and minimum blood oxygen. Among all the patients, those who underwent the titration test accounted for 20.6% (63/306). Multivariate analysis showed that sleep efficiency (p < 0.001) and AHI (p < 0.001) were independent factors for patients to accept titration test. OSA patients with hypertension had a low acceptance of titration therapy. These people with higher sleep efficiency and AHI were more likely to receive autotitration.

Keywords: obstructive sleep apnea, hypertension, titration test, sleep efficiency, apnea hypopnea index

INTRODUCTION

Sleep apnea hypopnea syndrome has a strong correlation with hypertension. Studies have found that more than 20% of hypertension patients have obstructive sleep apnea (OSA), and the prevalence of hypertension in OSA patients exceeds 50% (1–3). Hypertension patients with OSA are mostly refractory, and the effect of antihypertensive drugs alone is not good, and there is no effective evidence to prove that antihypertensive drugs can affect the severity of OSA patients. Therefore, such patients need to apply continuous positive airway pressure (CPAP) at the same time (4–6). Meta-analysis and randomized controlled trials have shown that CPAP can lower the blood pressure of OSA patients by about 2 mmHg. Although the effect of lowering blood pressure is relatively mild, it can still have a beneficial effect on the prognosis of cardiovascular disease outcomes (7–11). For adult patients with OSA and hypertension, the benefits of using CPAP therapy may outweigh the potential harm and burden caused by no intervention (12).
CPAP is usually set at a fixed pressure to prevent the upper airway from collapsing. The reference standard for determining the fixed pressure is the nocturnal CPAP titration study with polysomnography (PSG) monitoring in the sleep laboratory. In the past, manual titration was often used, but this method was time-consuming and expensive (13). A new type of automatic positive airway pressure (APAP) device can automatically adjust the pressure according to the physiological signals measured by the instrument. This method can reduce costs and improve the availability of treatment (14). Compared with the traditional CPAP titration method, OSA patients who took the APAP titration clinical pathway have the same or even better compliance with CPAP treatment (15, 16).

However, the reception and use of CPAP therapy is not ideal. Only 27.9% of OSA patients who had been prescribed CPAP received the test (17). The acceptance rate for elderly patients is 31.5% (18) and that of moderate to severe patients is 57.8% (19). Therefore, the acceptance and compliance of CPAP treatment has become a key issue for this group of people. At present, research on subjects such as OSA patients combined with hypertension in China is still very limited.

This study retrospectively analyzed 306 OSA patients with hypertension from October 2018 to December 2019. The purpose of the study is to investigate the clinical characteristics of patients with OSA and hypertension and the acceptance status of the titration test.

MATERIALS AND METHODS

Study Population

This was a retrospective case series of patients diagnosed with OSA and hypertension at the Sleep Center of Beijing Tiantan Hospital between October 2018 to December 2019. A total of 306 patients were included. OSA is defined as patients who reported apnea hypopnea index (AHI) ≥5/h after completing PSG (20), and hypertension is defined as having been diagnosed by a doctor and recommended for medical treatment. The patients included in the study had no other comorbidities. All the patients completed polysomnography (PSG) on the first night, and then people who accepted the titration test would be scheduled for the APAP titration test with an oral-nasal mask on the second night. Both tests were done in the sleep laboratory for full-night. APAP pressure setting was based on the results of the previous night’s PSG report to get an appropriate range. The research protocol was approved by the Medical Ethics Committee of Beijing Tiantan Hospital and the Medical Ethics Committee of Capital Medical University.

Scale Evaluation

Before starting PSG, each participant completed baseline information, medical history, and related scale evaluations, including Insomnia Severity Index (ISS) and Epworth Sleepiness Scale (ESS), Montreal Cognitive Assessment (MoCA), Hamilton Anxiety Rating Scale (HAMA), and Hamilton Depression Rating Scale-17 (HAMD). The scale evaluation is a routine examination of the patients in the sleep center, which was completed by professional clinicians, and all the patients’ informed consent had been obtained. Other information could be obtained from the patients’ medical records.

PSG

The sleep technicians conducted at least 6 h of standard nocturnal polysomnography research. The standard PSG record includes 6 electroencephalogram (EEG) leads (F3, F4, C3, C4, O1, and O2), 1 electrocardiograph (ECG) channel, 2 electrooculogram channels, 4 electromyography channels (bilateral jaws and bilateral lower limbs), video surveillance, thoracic breathing channel, abdominal breathing channel, the airflow of the nose and mouth is recorded by the thermal sensor, the position change is recorded by the position sensor, and the oxygen saturation is recorded by the fingertip oximeter. All the PSG data were confirmed by polysomnography technology experts according to the American Academy of Sleep Medicine 2007 standard. Obstructive apnea is defined as the need to reduce the airflow by 80–100% for at least 10 s, and the continuous breathing effort is recorded in the chest and abdominal movement channels. AHI is calculated as the total number of apneas and hypopneas during sleep per hour. The definition of sleep efficiency is the ratio of total sleep time to total recording time. For OSA patients with hypertension, sleep specialists will recommend them complete the APAP titration test in the laboratory, and let them understand the basic principles, benefits and possible side effects of CPAP.

Statistical Analysis

Use SPSS22.0 for data collection and statistical analysis. The comparison between the two groups uses independent sample t-test (when the continuous variable obeys the normal distribution) and the Mann-Whitney U test (when the continuous variable obeys the non-normal distribution); the comparison among three groups uses analysis of variance (when the continuous variable obeys a normal distribution) and Kruskal-Wallis H test (when the continuous variable obeys a non-normal distribution), the Bonferroni method is used for the post-test. The chi-square test was used to compare categorical variables between groups. Spearman rank test was used for correlation analysis. All variables related to the acceptance of titration test are introduced into the multiple logistic regression model (forward, conditional). The multivariate odds ratio (OR) and 95% confidence interval (CI) are given. A bilateral P-value < 0.05 was considered statistically significant.

RESULTS

Overall Demographic Data and Polysomnography Parameters

Table 1 shows the overall characteristics of the 306 OSA patients with hypertension included in this study. There were 213 males and 93 females. The average age of the patients was 55.8 ± 12.9 years. All patients had symptoms such as snoring, daytime sleepiness, cognitive decline or depression in varying degrees. 42% of patients have periodic limb movements.
TABLE 1 | Characteristics of the patients according to the severity of OSA.

| Characteristics | Total cohort (n = 306) | 5 ≤ AHI < 15 (n = 69) | 15 ≤ AHI < 30 (n = 86) | AHI ≥ 30 (151) | p-value |
|----------------|------------------------|------------------------|--------------------------|----------------|---------|
| Demographic and clinical characteristics | | | | | |
| % of total | 100 | 22.5 | 28.1 | 49.3 | | |
| Age, y | 55.8 ± 12.9 | 56.5 ± 12.6 | 57.5 ± 11.9 | 54.5 ± 13.4 | 0.185 |
| Male, n (%) | 213 (69.6) | 38 (55.1) | 49 (57) | 126 (69.6) | <0.001 |
| BMI, kg/m² | 27.1 ± 4.3 | 25.8 ± 3.6 | 26.2 ± 3.7 | 28.1 ± 4.6 | <0.001 |
| Tobacco use, n (%) | 139 (45.4) | 29 (42) | 32 (37.2) | 78 (51.7) | 0.081 |
| Alcohol drinking, n (%) | 170 (55.6) | 34 (49.3) | 41 (47.7) | 95 (62.9) | 0.037 |
| Polysomnographic data | | | | | |
| Sleep efficiency,% | 70.3 ± 16.5 | 72.7 ± 16.4 | 68.2 ± 17.7 | 70.5 ± 15.8 | 0.185 |
| Sleep stage,%TST | | | | | |
| REM | 15.7 ± 6.8 | 17.5 ± 7.4 | 15.3 ± 6.9 | 15.2 ± 6.3 | 0.084 |
| N1 | 25 ± 17.1 | 18 ± 11.2 | 21.3 ± 15.1 | 30.3 ± 18.8 | <0.001 |
| N2 | 54.2 ± 15.3 | 59 ± 12.9 | 56.8 ± 12.2 | 50.5 ± 17 | <0.001 |
| N3 | 5 ± 6.2 | 5.5 ± 5.8 | 6.6 ± 7.9 | 4 ± 4.9 | 0.019 |
| Mean SpO₂,% | 94.6 ± 2.9 | 95.6 ± 1.4 | 95.3 ± 3 | 93.8 ± 3.1 | <0.001 |
| Lowest SpO₂,% | 81.4 ± 9.6 | 87 ± 5.1 | 85.4 ± 5.9 | 76.7 ± 10.4 | <0.001 |
| Scale | | | | | |
| ISI | 9.9 ± 7.4 | 9.6 ± 7.8 | 12.3 ± 7.9 | 8.7 ± 6.6 | 0.03 |
| ESS | 7.7 ± 5.6 | 7.4 ± 5.8 | 7 ± 6.3 | 8.3 ± 5.1 | 0.197 |
| MoCA | 23.6 ± 4.9 | 23.4 ± 4.2 | 22.8 ± 5.7 | 24.3 ± 4.6 | 0.061 |
| HAMA | 9.1 ± 7.1 | 9.6 ± 8.4 | 10.9 ± 8.1 | 7.9 ± 5.6 | 0.15 |
| HAMD-17 | 5.8 ± 5.2 | 6.4 ± 5.7 | 7 ± 6.1 | 4.9 ± 4.3 | 0.171 |

Data are presented as number (%) or as mean ± standard deviation, as appropriate. The number in bold indicates significance (p < 0.05).

BMIs, body mass index; TST, total sleep time; REM, rapid eye movement; N1, non-REM (NREM) stage 1; N2, non-REM (NREM) stage 2; N3, non-REM (NREM) stage 3; Mean SpO₂, Mean oxygen saturation; Lowest SpO₂, Lowest oxygen saturation; ISS, Insomnia Severity Index; ESS, Epworth Sleepiness Scale; MoCA, Montreal Cognitive Assessment; HAMA, Hamilton Anxiety Scale; HAMD-17, Hamilton Depression Scale—17.

Characteristics of OSA Patients With Different Severity

306 patients received PSG in the laboratory, and all patients had sleep apnea. Divide the patients into three groups according to AHI: 69 cases were mild (5 ≤ AHI < 15), 86 cases were moderate (15 ≤ AHI < 30), and 151 cases were severe (AHI ≥ 30). Age, smoking history, sleep efficiency, rapid eye movement accounted for total sleep time (REM%) and most scale scores were not statistically different among OSA patients of different severity (all P > 0.05). The post-examination found that compared with patients in the mild and moderate groups, the severe group had more male patients, higher body mass index (BMI) and non-REM stage 1 accounted for total sleep time (N1%), and lower non-REM stage 2 accounted for total sleep time (N2%), average and minimum blood oxygen.

The Status of Receiving Titrination Test

63 patients accepted titration test, and 243 patients were not treated (Table 2). Although gender and minimum blood oxygen saturation were found to be significantly related to AHI, multicollinearity was not serious. Therefore, age, gender, educational background, sleep efficiency, AHI, and minimum blood oxygen saturation were included in the logistic regression model. The dependent variable is divided into accepting titration test and not accepting titration test. Multivariate analysis showed that sleep efficiency (OR = 1.043, 95%CI: 1.02–1.067, P < 0.001) and AHI (OR = 1.022, 95%CI: 1.01–1.034, P < 0.001) were independent factors related to titration test in patients with OSA and hypertension (Table 3).

DISCUSSION

This study is the first to investigate the sleep structure and treatment status of OSA patients with hypertension. It was found that severe group had a higher BMI and N1%, and a lower N2%. In addition, patients with OSA and hypertension have low acceptance of titration tests. The results showed that only 20.6% of the 306 patients underwent the titration test. Multivariate analysis showed that AHI and sleep efficiency were independent factors for OSA patients to undergo titration tests.

In a longitudinal study of weight change and sleep-disordered breathing, baseline BMI was a significant predictor of AHI changes. For every 1 kg/m² added in baseline BMI, AHI was expected to increase by about 1% (21). During sleep in OSA patients, complete or partial obstruction of the upper airway occurs repeatedly, often accompanied by decreased blood oxygen.
The continuous process of sleep is interrupted to form fragmented sleep. Issa and Sullivan found that OSA patients were more likely to collapse in the upper airway during light sleep stage when they evaluated the upper airway obstruction technique (22). Therefore, compared with mild and moderate patients, severe patients have more apneas, and then N1% will be higher.

The apnea that occurs during sleep in OSA patients can cause hypoxia and high carbon dioxide partial pressure, stimulate peripheral and central chemoreceptors, re-regulate the blood pressure threshold, and develop essential hypertension. In addition, oxidative stress and inflammation are also the mechanisms that can cause hypertension in patients with OSA (23, 24).

A team has found that OSA and hypertension have an interactive effect on the progression of carotid atherosclerosis and the level of inflammatory markers of atherosclerosis in the blood (such as interleukin-6 and pentapeptidase-3). Compared with OSA patients with normal blood pressure, hypertension patients without OSA or the control group, the carotid artery intima-media thickness and early markers of atherosclerosis were significantly increased (25, 26). Therefore, OSA patients with hypertension often have

### TABLE 2: Characteristics of the patients according to the treatments for OSA.

| Characteristics                             | Total cohort (n = 306) | Titration test (n = 63) | No treatment (n = 243) | p-value |
|---------------------------------------------|-----------------------|------------------------|------------------------|---------|
| Demographic and clinical characteristics   |                       |                        |                        |         |
| % of total                                  | 100                   | 20.6                   | 79.4                   |         |
| Age, y                                      | 55.8 ± 12.9           | 51.5 ± 12.1            | 56.9 ± 12.9            | 0.005   |
| Male, n (%)                                 | 213 (69.6)            | 51 (81)                | 162 (66.7)             | 0.028   |
| BMI, kg/m²                                  | 27.1 ± 4.3            | 27.8 ± 4.7             | 26.9 ± 4.2             | 0.221   |
| Tobacco use, n (%)                          | 139 (45.4)            | 30 (47.6)              | 109 (44.9)             | 0.695   |
| Alcohol drinking, n (%)                    | 170 (55.6)            | 38 (60.3)              | 132 (54.3)             | 0.393   |
| Education background, n (%)                 |                       |                        |                        | 0.045   |
| ≤9 years                                    | 116 (37.9)            | 17 (27)                | 99 (40.7)              |         |
| >9 years                                    | 190 (62.1)            | 46 (73)                | 144 (59.3)             |         |
| Polysomnographic data                       |                       |                        |                        |         |
| Sleep efficiency, %                         | 70.3 ± 16.5           | 77.2 ± 13.6            | 68.6 ± 16.8            | <0.001  |
| Sleep stage, %TST                           |                       |                        |                        |         |
| REM                                         | 15.7 ± 6.8            | 15.5 ± 5.3             | 15.8 ± 7.1             | 0.877   |
| N1                                          | 25 ± 17.1             | 24.2 ± 15.5            | 25.2 ± 17.6            | 0.93    |
| N2                                          | 54.2 ± 15.3           | 55.4 ± 14.1            | 53.9 ± 15.6            | 0.615   |
| N3                                          | 5 ± 6.2               | 4.9 ± 5.3              | 5.1 ± 6.4              | 0.881   |
| AHl, events/h                               | 34.9 ± 23.5           | 44.7 ± 25.6            | 32.3 ± 22.2            | <0.001  |
| Mean SpO₂, %                                | 94.6 ± 2.9            | 94.4 ± 3.3             | 94.7 ± 2.8             | 0.466   |
| Lowest SpO₂, %                              | 81.4 ± 9.6            | 78.8 ± 11.7            | 82.1 ± 8.8             | 0.038   |
| Scale                                       |                       |                        |                        |         |
| ISI                                         | 9.9 ± 7.4             | 10 ± 7.3               | 9.9 ± 7.4              | 0.96    |
| ESS                                         | 7.7 ± 5.6             | 7.63 ± 4.7             | 7.8 ± 5.9              | 0.854   |
| MoCA                                        | 23.6 ± 4.9            | 24.6 ± 3.6             | 23.4 ± 5.1             | 0.265   |
| HAMA                                        | 9.1 MA5.1             | 8.9 MA5.4              | 9.2 MA5.3              | 0.82    |
| HAMD-17                                     | 5.8 ± 5.2             | 6 ± 5.6                | 5.7 ± 5.1              | 0.924   |

Data are presented as %. Bold font indicates variables with statistically significant differences between clusters (p < 0.05). BMI, body mass index; TST, total sleep time; REM, rapid eye movement; N1, non-REM (NREM) stage 1; N2, non-REM (NREM) stage 2; N3, non-REM (NREM) stage 3; AHl, apnoea-hypopnoea index; Mean SpO₂, Mean oxygen saturation; Lowest SpO₂, Lowest oxygen saturation; ISS, Insomnia Severity Index; ESS, Epworth Sleepiness Scale; MoCA, Montreal Cognitive Assessment; HAMA, Hamilton Anxiety Scale; HAMD-17, Hamilton Depression Scale-17.

### TABLE 3: Multivariate analysis of independent factors associated with the decisions for titration treatment-test.

| Variable       | Multivariate analysis | OR  | 95%CI | p-value |
|----------------|-----------------------|-----|-------|---------|
| Age            |                       |     |       | 0.595   |
| Sex            |                       |     |       | 0.213   |
| Education background |                   |     |       | 0.123   |
| Sleep efficiency |                    | 1.043 | 1.02–1.067 | <0.001 |
| AHl            |                       | 1.022 | 1.01–1.034 | <0.001 |
| Lowest SpO₂    |                       | 0.629 |       |         |

The number in bold indicates significance (p < 0.05). AHl, apnoea-hypopnoea index; Lowest SpO₂, Lowest oxygen saturation.
more serious target organ damage. This kind of crowd should be highly valued by doctors and be given early treatment intervention.

The American Academy of Sleep Medicine recommends that clinicians use CPAP to treat adult OSA patients with hypertension (12). Studies have confirmed that in patients with hypertension and OSA, after long-term use of CPAP standardized treatment, daytime systolic blood pressure is significantly reduced, and daytime sleepiness has also been improved (27).

However, the treatment condition is not ideal. In the past 20 years, the overall non-compliance rate of CPAP was 34.1% (28). Many previous studies have focused on compliance with CPAP treatment, but about 5–50% of patients who were recommended to use CPAP refused this treatment or stopped treatment within the 1st week (29). Therefore, the acceptance of CPAP treatment should also be considered. CPAP pressure titration test is an important link that would affect patients' subsequent treatment. Previous studies investigated the reasons why patients did not receive CPAP treatment, including patients thought they did not need treatment, did not know how to treat them, lacked knowledge of the disease, and believed that the machine was inconvenient to use. But even if patients are given standardized consultation before APAP titration, the acceptance of CPAP by OSA patients is still very low (19).

A previous study on elderly OSA patients showed that compared with mild patients, moderate AHI patients and severe patients are more likely to receive CPAP (18). Our study also reached a similar conclusion, and found that AHI is an independent factor in the titration test for patients with OSA and hypertension. Although previous studies have pointed out that the ESS score is an important predictor of CPAP acceptance, our study did not find an association between ESS score and acceptance. Some studies have reported that the accuracy of this scale was dependent on the participants' gender, psychological variables and subjective perception (30–32). Therefore, it is controversial to take ESS score as a predictor of acceptance. Previous studies have also found that lower CPAP acceptance is related to living alone, mild symptoms (especially drowsiness), less skills, impaired cognitive ability, comorbidities, and neurological deficits (33). Economic incentives can increase the acceptance of CPAP by low-income patients (34). However, these conclusions have not been confirmed in this study, so multicenter, large sample size and more comprehensive studies are needed to verify in the future.

For the first time our study found that sleep efficiency is an independent factor in the titration test for patients with OSA and hypertension. Sleep efficiency itself is affected by many factors. A laboratory PSG-based study assessed patients’ sleep quality and explored factors related to poor sleep. In a multivariate analysis, it was found that older, male, and severe OSA patients are more likely to suffer from sleep deprivation (35). However, this study found that the multicollinearity between sleep efficiency and the variables mentioned above is not serious, so all of them can be included in the regression model together. In addition, because the PSG in the laboratory has a “first night effect”, it will greatly reduce the patient's sleep efficiency (36). However, there was no significant difference in sleep efficiency between the PSG laboratory group and the home monitoring group (37). If the “first night effect” of patients with OSA and hypertension can be reduced, and their sleep efficiency can be improved, then their acceptance of the CPAP titration test can be boosted.

This study still has certain limitations. First, the sample size was relatively small and came from a single center. Furthermore, the retrospective design prevented the investigation of the patients’ specific blood pressure at that time. For OSA patients, especially those with hypertension, CPAP treatment is the key to improving the quality of life, reducing accidents and improving cognitive outcomes (38). Successfully promoting the use of CPAP for patients depends on the medical team’s connection and problem solving in each step of the therapeutic process. More research is necessary to determine ways to improve patients’ acceptance of CPAP.

CONCLUSION

In summary, it can be found that a large proportion of OSA patients with hypertension do not receive correct treatment guidance, and the rate of receiving a titration test is at a low level. Patients with higher AHI and higher sleep efficiency are more likely to undergo a titration test. In the future, more efforts are needed to solve these patients’ understanding to the disease, and more research is needed to comprehensively explore the factors that influence patients’ treatment decision. In this way, we could draw up personalized and optimal treatment protocols for these people who are in urgent need of treatment.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of Beijing Tiantan Hospital and the Medical Ethics Committee of Capital Medical University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

XZ and C-XW designed the study. XZ, C-XW, NZ, YY, SW, PY, and B-YG collected and analyzed the data. PY and B-YG interpreted the results. XZ drafted the manuscript. XZ, YY, and SW were major contributors in writing and editing the manuscript. All authors read, revised, and approved the final manuscript.

FUNDING

This study was funded by National Key Research & Development Program of China (No. 2020YFC2005304) and Capital’s Funds for Health Improvement and Research (2020-2-2044).
REFERENCES

1. Drager LF, Genta PR, Pedrosa RP, Nerbass FB, Gonzaga CC, Krieger EM, et al. Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. Am J Cardiol. (2010) 105:1135–9. doi: 10.1016/j.amjcard.2009.12.017

2. Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo J, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. (2003) 289:2560–72. doi: 10.1001/jama.289.19.2560

3. Kiely J, McNicholas W. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. Eur Respir J. (2000) 16:128–33. doi: 10.1183/09031983.2000.16a23.x

4. Kraiczi H, Hedner J, Peker Y, Grote L. Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. Am J Respir Crit Care Med. (2000) 161:1423–8. doi: 10.1164/ajrccm.161.5.990924

5. Torres G, Sanchez-de-la-Torre M, Barbe F. Relationship between OSA and hypertension. Am J Respir Crit Care Med. (1994) 150:72–7. doi: 10.1164/ajrccm.150.1.80209024

6. Carlson J, Hedner J, Ejnell H, Peterson L. High prevalence of obstructive sleep apnea syndrome. Eur Respir J. (2007) 30:248–53. doi: 10.1183/09031983.2007.16031283

7. Bazzano L, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension. (2007) 50:417–23. doi: 10.1161/HYPERTENSIONAHA.106.085175

8. Bratton D, Stradling J, Barbe F, Kohler M. Effect of CPAP on blood pressure in patients with minimally symptomatic obstructive sleep apnoea: a meta-analysis using individual patient data from four randomised controlled trials. Thorax. (2014) 69:1128–35. doi: 10.1136/thoraxjnl-2013-204993

9. Fava C, Dorigoni S, Dalle Vedove F, Danese E, Montagnana M, Guidi G, et al. Effect of CPAP on blood pressure in patients with OSA/hypopnea a systematic review and meta-analysis. Chest. (2014) 145:762–71. doi: 10.1378/chest.13-1115

10. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. (2003) 362:1527–35. doi: 10.1016/S0140-6736(03)12473-3

11. Sapiña-Beltrán E, Torres G, Martínez-Alonso M, Sánchez-de-la-Torre M, Franch M, Bravo C, et al. Rationale and methodology of the SARAH trial: long-term cardiovascular outcomes in patients with resistant hypertension and obstructive sleep apnea. Arch Bronconeumol. (2018) 54:518–23. doi: 10.1016/j.arbes.2018.03.002

12. Patil S, Ayappa I, Caples S, Kimoff R, Patel S, Harrod C. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. (2019) 15:335–43. doi: 10.5664/jcsm.7640

13. Morgenthaler T, Aurora R, Brown T, Zak R, Alessi C, Boechcke B, et al. Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of Sleep Medicine report. Sleep. (2008) 31:141–7. doi: 10.1093/sleep/31.1.141

14. McArdle N, Singh B, Murphy M, Gain K, Maguire C, Mutch S, et al. Continuous positive airway pressure titration for obstructive sleep apnoea: a randomised controlled trial. Thorax. (2010) 65:606–11. doi: 10.1136/thx.2009.16756

15. Mulgrew A, Fox N, Ayas N, Ryan C. Diagnosis and initial management of obstructive sleep apnea without polysomnography: a randomized validation study. Ann Intern Med. (2007) 146:157–66. doi: 10.7326/0003-4819-146-3-200702060-00004

16. Berry R, Gill H, Thompson L, McLaurin V. Portable monitoring and autotitration versus polysomnography for the diagnosis and treatment of sleep apnea. Sleep. (2008) 31:1423–31.

17. Rezaie L, Phillips D, Khaziea H. Barriers to acceptance and adherence to continuous positive airway pressure therapy in patients with obstructive sleep apnea: a report from Kermanshah province, western Iran. Patient Prefer Adherence. (2012) 12:1299–304. doi: 10.2147/PPA.S65905

18. Yang MC, Lin CY, Lan CC, Huang CY, Huang YC, Lim CS, et al. Factors affecting CPAP acceptance in elderly patients with obstructive sleep apnea in Taiwan. Respir Care. (2013) 58:1504–13. doi: 10.4187/respcare.02176

19. Lee CHK, Leow LC, Song PL, Li H, Ong TH. Acceptance and adherence to continuous positive airway pressure therapy in patients with Obstructive Sleep Apnea (OSA) in a Southeast Asian privately funded healthcare system. Sleep Sci. (2017) 10:57–63. doi: 10.5935/1984-0063.20170010

20. Peppard P, Young T, Barnet J, Palta M, Hagen E, Hla K. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. (2013) 177:1006–14. doi: 10.1093/aje/kws342

21. Peppard P, Young T, Palta M, Dempsey J, Skatrud J, Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. (2000) 284:3015–21. doi: 10.1001/jama.284.23.3015

22. Issa F, Sullivan C. Upper airway closing pressures in obstructive sleep apnea. J Appl Physiol Respir Environ Exerc Physiol. (1984) 57:520–7. doi: 10.1152/jappl.1984.57.2.520

23. Somers V, Dyken M, Mark A, Abboud F. Sympathetic-nerve activity during sleep in normal subjects. N Engl J Med. (1993) 328:303–7. doi: 10.1056/NEJM199302043280502

24. Li N, Yao X, Zhu J, Yang J, Liu K, Wang Y, et al. Higher levels of plasma TNF-alpha and neuropeptide Y in hypertensive patients with obstructive sleep apnea syndrome. Clin Exp Hypertens. (2010) 32:54–60. doi: 10.3109/10641560902993087

25. Damiani MF, Scoditti C, Bega E, Scoditti A, Fanfulla F. Additive effects of OSA and hypertension on endothelial damage. Chest. (2017) 151:520–1. doi: 10.1016/j.chest.2016.11.046

26. Damiani M, Zito A, Carraù P, Falcone V, Bega E, Scicchitano P, et al. Obstructive sleep apnea, hypertension, and their additive effects on atherosclerosis. Biochem Res Int. (2015) 2015:984193. doi: 10.1155/2015/984193

27. Huang Z, Liu Z, Luo Q, Zhao Q, Zhao Z, Ma X, et al. Long-term effects of continuous positive airway pressure on blood pressure and prognosis in hypertensive patients with coronary heart disease and obstructive sleep apnea: a randomized controlled trial. Am J Hypertens. (2015) 28:300–6. doi: 10.1093/ajh/hpu147

28. Rotenberg B, Murariu D, Pang K. Trends in CPAP adherence over twenty years of data collection: a flattened curve. J Otolaryngol Head Neck Surg. (2016) 45:43. doi: 10.1186/s40463-016-0158-0

29. Engleman H, Wild M. Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS). Sleep Med Rev. (2003) 7:81–99. doi: 10.1016/s1208-8959(03)00002-5

30. Chervin RD, Aldrich MS. The Epworth Sleepiness Scale may not reflect predictors of CPAP use for the treatment of obstructive sleep apnea. J Sleep Res. (2013) 22:103. doi: 10.1111/j.1365-2869.1998.0123x

31. Lewis K, Seale L, Bartle I, Watkins A, Ebdon P. Early predictors of CPAP use for the treatment of obstructive
sleep apnea. Sleep. (2004) 27:134–8. doi: 10.1093/sleep/27.1.134

34. Tarasiuk A, Reznor G, Greenberg-Dotan S, Reuveni H. Financial incentive increases CPAP acceptance in patients from low socioeconomic background. PLoS ONE. (2012) 7:e33178. doi: 10.1371/journal.pone.0033178

35. Harrison E, Roth R, Lobo J, Kang H, Logan J, Patel S, et al. Sleep time and efficiency in patients undergoing laboratory-based polysomnography. J Clin Sleep Med. (2021) 10.5664/jcsm.9252 doi: 10.5664/jcsm.9252

36. Le Bon O, Minner P, Van Moorsel C, Hoffmann G, Gallego S, Lambrecht L, et al. First-night effect in the chronic fatigue syndrome. Psychiatry Res. (2003) 120:191–9. doi: 10.1016/S0165-1781(03)00185-9

37. Zancanella E, do Prado L, de Carvalho L, Machado Júnior A, Crespo A, do Prado G. Home sleep apnea testing: an accuracy study. Sleep Breath. (2021) 10.1007/s11325-021-02372-6 doi: 10.1007/s11325-021-02372-6

38. Weaver TE. Novel aspects of CPAP treatment and interventions to improve CPAP adherence. J Clin Med. (2019) 8:2220. doi: 10.3390/jcm8122220

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Zhang, Yang, Wang, Yu, Guan and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.